About this item:

578 Views | 155 Downloads

Author Notes:

Correspondence: Dr. L. Yang; Email: Lyang02@emory.edu

Dr. Y.-S. Cho and Dr. G. Y. Lee contributed equally to this study.

Acknowledgments: We thank Dr. Fengzhi Li for providing the survivin shRNA sequence, Dr. Steven Dowdy for information on the SV40 nuclear localization sequence, Dr. Rosa Hwang for luciferase gene stable MIA PaCa-2 cell line, and Dr. Adam Marcus for the MCF-7 GFP stable cell line and for his assistance with the Olympus OV-100 imaging system at the Emory Integrated Cell Imaging Core.

Subjects:

Research Funding:

This research project was supported by the following NIH grants: U01CA151810 (Yang and Mao), R01CA154129A01 (Yang), U54 CA119338 (Nie), and P50CA128613 (Shin).

Dr. Young-Seok Cho was supported by a Songeui Scholar Research Grant funded by the Catholic University of Korea.

Dr. Lily Yang is the Nancy Panoz Chair of Surgery in Cancer Research.

Targeted Delivery of siRNA-Generating DNA Nanocassettes Using Multifunctional Nanoparticles

Show all authors Show less authors

Tools:

Journal Title:

Small

Volume:

Volume 9, Number 11

Publisher:

, Pages 1964-1973

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Molecular therapy using a small interfering RNA (siRNA) has shown promise in the development of novel therapeutics. Various formulations have been used for in vivo delivery of siRNAs. However, the stability of short double-stranded RNA molecules in the blood and efficiency of siRNA delivery into target organs or tissues following systemic administration have been the major issues that limit applications of siRNA in human patients. In this study, multifunctional siRNA delivery nanoparticles are developed that combine imaging capability of nanoparticles with urokinase plasminogen activator receptor-targeted delivery of siRNA expressing DNA nanocassettes. This theranostic nanoparticle platform consists of a nanoparticle conjugated with targeting ligands and double-stranded DNA nanocassettes containing a U6 promoter and a shRNA gene for in vivo siRNA expression. Targeted delivery and gene silencing efficiency of firefly luciferase siRNA nanogenerators are demonstrated in tumor cells and in animal tumor models. Delivery of survivin siRNA expressing nanocassettes into tumor cells induces apoptotic cell death and sensitizes cells to chemotherapy drugs. The ability of expression of siRNAs from multiple nanocassettes conjugated to a single nanoparticle following receptor-mediated internalization should enhance the therapeutic effect of the siRNA-mediated cancer therapy.

Copyright information:

© 2013 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

Export to EndNote